Compound class:
Synthetic organic
Comment: OPS-2071 is a fluoroquinolone antibacterial compound, with broad-spectrum activity against both Gram-positive and Gram-negative bacteria [2]. It is a clinical candidate being developed by Otsuka Pharmaceutical (Tokyo, Japan) as a treatment for intestinal infections, particularly those caused by Clostridioides difficile. Functionally, it is a type II DNA topoisomerase inhibitor with similar activity against DNA gyrase and DNA topoisomerase 4 [1].
|
|
References |
1. Oka D, Changkwanyeun R, Yamaguchi T, Nakajima C, Suzuki Y, Matsumoto M. (2022)
In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria. J Antimicrob Chemother, 77 (12): 3248-3255. [PMID:36101508] |
2. Oka D, Yamaya N, Kuno T, Asakawa Y, Shiragiku T, Chen L, Xue J, Mamuti A, Ye F, Sun J et al.. (2021)
In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile. Antimicrob Agents Chemother, 65 (4). [PMID:33495229] |